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Objective: Current clinical trials evaluating carotid stenting have focused on high-risk patients and may not reflect the
broad population of patients with carotid stenosis who undergo treatment to prevent stroke. The Carotid Revascular-
ization Using Endarterectomy or Stenting Systems (CaRESS) phase I study is a multicenter, prospective, nonrandomized
trial designed to address the question of whether carotid stenting (CAS) with cerebral protection is comparable to carotid
endarterectomy (CEA) in patients with symptomatic and asymptomatic carotid stenosis.
Methods: Patients with symptomatic (with >50% stenosis) or asymptomatic (with >75% stenosis) carotid stenosis were
entered into the study in a 2:1 ratio of carotid stent and GuardWire Plus distal protection device. This unique trial model
was developed through collaboration with the International Society of Endovascular Specialists, the Food and Drug
Administration, the Centers for Medicare and Medicaid Services, the National Institutes of Health, and industry
representatives. The primary end points included death and stroke at 30 days and a composite 1-year end point of death,
stroke, or myocardial infarction (MI) from 0 to 30 days and death or stroke from 31 days to 1 year. The secondary end
points included residual stenosis, restenosis, repeat angiography, and carotid revascularization at 30 days and 1 year and
quality-of-life changes at 1 year.
Results: A total of 397 patients (254 CEA and 143 CAS) were enrolled in the study: 32% were symptomatic and 68% were
asymptomatic. There were no significant differences in patient characteristics, symptoms, or surgical risk profiles between
groups at baseline. Kaplan-Meier analysis revealed no significant differences in combined death/stroke rates at 30 days
(3.6% CEA vs 2.1% CAS) or at 1 year (13.6% CEA vs 10.0% CAS). Similarly, there was no significant difference in the
combined end point of death, stroke, or MI at 30 days (4.4% CEA vs 2.1% CAS) or at 1 year (14.3% CEA vs 10.9% CAS).
There were no significant differences between CEA and CAS in the secondary end points of residual stenosis (0% CEA vs
0.9% CAS), restenosis (3.6% CEA vs 6.3% CAS), repeat angiography (2.1% CEA vs 3.6% CAS), carotid revascularization
(1.0% CEA vs 1.8% CAS), or change in quality of life (1.56 points CEA vs 4.22 points CAS).
Conclusions: The CaRESS phase I study suggests that the 30-day and 1-year risk of death, stroke, or MI with CAS is
equivalent to that with CEA in symptomatic and asymptomatic patients with carotid stenosis. ( J Vasc Surg 2005;42:
213-9.)In current clinical practice, carotid stenting (CAS) has
emerged as a viable alternative for patients who are deemed
at high risk for surgery or poor candidates for carotid
endarterectomy (CEA), which is considered the standard of
care.1 This is demonstrated by trials such as ACCULINK
for Revascularization of Carotids in High-Risk Patients
(ARCHeR) (Guidant Corporation, Menlo Park, Calif),
Stenting and angioplasty with protection in patients at high
risk for endarterectomy trial (SAPPHiRE) (Cordis Corpo-
ration, Warren, NJ), Evaluation of the Medtronic AVE
self-expandable carotid stent system with distal protection
in the treatment of carotid stenosis (MAVEerILC)
(Medtronic Vascular, Santa Rosa, Calif), Carotid artery
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EX/EZ and the EndoTex NexStent trial (CABernET)
(Boston Scientific/EndoTex, Cupertino, Calif), and Reg-
istry study to evaluate the Neuroshield bare wire cerebral
protection system and X-Act Stent in patients at high risk
for carotid endarterectomy (SECuRITY) (Abbott Vascular,
Redwood City, Calif).2-6 However, there is considerable
variability in the definition of high risk among these trials
based on inclusion criteria.
Because the recent trials have focused on relatively
narrow indications of high-risk patient populations, they
are unlikely to answer the overall question of whether CAS
with distal, embolic protection is equivalent to the standard
of care (ie, CEA) for most patients with carotid stenosis
who are at risk for stroke. The two most referenced trials in
the current clinical decision-making process for carotid
stenosis are the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) and the Asymptomatic
Carotid Atherosclerosis Study (ACAS), in which inclusion
for treatment is based on symptoms rather than surgical
risk.7,8 Just as patients undergo open surgical repair (ie,
CEA) on the basis of symptoms rather than surgical risk,
the safety and efficacy of CAS should not be limited only to
a high-risk population. The Carotid Revascularization
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National Institutes of Health uses symptomatology to de-
termine eligibility.9 Similarly, the Carotid Revasculariza-
tion Using Endarterectomy or Stenting Systems (CaRESS)
trial was designed on the basis of the broad category of
standard risk by using symptomatology as a defining crite-
rion for stratification in the study.10
CaRESS is a unique trial that developed through early
collaboration between the International Society of Endo-
vascular Specialists, the Food andDrug Administration, the
Centers for Medicare and Medicaid Services, the National
Institutes of Health, and the industry. The 30-day results
have been previously published.10 This article presents the
comprehensive 1-year follow-up results of the CaRESS
phase I trial.
METHODS
Study design. The CaRESS trial is a multicenter, pro-
spective, nonrandomized equivalence cohort study that
was designed to evaluate the safety and effectiveness of CAS
with embolic protection compared with CEA in a broad-
risk population with symptomatic and asymptomatic ca-
rotid stenosis. Outcomes were measured at 30 days and 1
year after the procedure. For purposes of comparison with
other published trials, results are also stratified by symp-
toms and by surgical risk. Lacking a uniform, standard
definition of high risk for trials such as ARCHeR, SAP-
PHiRE, MAVErIC, CABernET, or SECuRITY, the defi-
nition published by Ouriel et al11 was used for this article.
High risk is defined as having any one of the following
criteria: (1) age 80 years or older, (2) New York Heart
Association class III/IV for congestive heart failure, (3)
chronic obstructive pulmonary disease, (4) contralateral
stenosis50%, (5) prior CEA or CAS, or (6) prior coronary
artery bypass grafting.11
This study was conducted in accordance with the Dec-
laration of Helsinki of 1996, the International Conference
on Harmonization guidelines for good clinical practice,
and Code of Federal Regulations 21 CFR 812 for Investi-
gational Device Exemptions. This trial was conducted un-
der a Sponsor-Investigator Device Exemption held by the
International Society of Endovascular Specialists. The
Monorail Wallstent (Boston Scientific Corporation,
Natick, Mass) CAS and GuardWire Plus (Medtronic Vas-
cular) distal protection devices were used in the CAS arm in
accordance with the instructions for use.10 Both Boston
Scientific Corporation and Medtronic Vascular provided
the devices free of charge and fully funded the study.
The CaRESS model was approved by the Food and
Drug Administration to allow multiple manufacturers to
(1) participate in one clinical trial for a broad-risk popula-
tion, (2) provide full use of control (CEA) data sets, (3)
provide an aggregate CAS data set for additional statistical
power, and (4) reduce the burden for an individual manu-
facturer conducting a similar trial for labeling approval.
This model will be implemented in phase II.
Information on study design, clinical site selection, and
patient enrollment has been previously published.10 A sum-mary of the indications for allocation to each study arm and
intervention techniques is provided here.
The clinical characteristics of the study patients, includ-
ing conditions such as diabetes, congestive heart failure,
hypercholesterolemia, and coronary artery disease, were
entered in the database on the basis of the history and
physical examination performed by the physician who pro-
vided clearance for the patient to undergo carotid interven-
tion.
The choice of treatment by CAS or CEA was based
solely on physician and patient preference. This design
more accurately reflects the true clinical environment.
Patients undergoing CAS were previously placed on
aspirin and ticlopidine or clopidogrel and heparinized dur-
ing the procedure to maintain an activated coagulation
time between 250 and 300 seconds. After the procedure,
these patients were maintained on aspirin (325 mg daily)
indefinitely and either clopidogrel or ticlopidine for 4
weeks. Access to the common carotid artery (CCA) with a
guide catheter was attained by using the standard tech-
niques of exchanging in the external carotid artery or CCA.
The filter wire was deployed above the lesion, and then the
wire was used as the platform for all percutaneous devices.
The filter was captured at the end of the procedure, and
final cervical carotid and intracranial carotid images were
obtained.
Patients undergoingCEAwere placed on aspirin before
the procedure. Additional appropriate medications were
prescribed per investigator discretion and institutional pro-
cedures. The choice of the specific technique of endarter-
ectomy was left to the treating physician.
End points. The primary end points for the phase I trial
included all-cause mortality or stroke within 30 days and 1
year of the procedure. The secondary end points included a
composite of 30-day all-causemortality, stroke, or acutemyo-
cardial infarction (AMI) and 1-year all-cause mortality or
stroke; residual stenosis, restenosis, repeat angiography, and
carotid revascularization at 30 days and 1 year; and quality-of-
life changes at 1 year. An independent data and safety moni-
toring board reviewed the centrally adjudicated clinical events
for safety.
Definitions. Stroke was defined as any localized neuro-
logical deficit lasting longer than 24 hours as assessed in a
standard neurologic examination by a neurologist and either
confirmed by a magnetic resonance imaging or head com-
puted tomographic scan or independently confirmed during
central adjudication. AMI was defined as any new pathologic
changes on electrocardiogram or total creatine kinase 2 or
more times the upper limit of normal with an increased
myocardial band fraction. Residual stenosis was defined as
more than 50% stenosis in the target lesion after the index
study procedure. Restenosis was defined as 75% narrowing
documented by ultrasonography or symptomatic narrowing
greater than 50% that required secondary treatment. The
Multidimensional Index of Life Quality (MILQ) question-
naire measured a weighted combination of mental health and
social and physical functioning items to evaluate quality of
life.11-13
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vanced Data Entry and Protocol Tracking data management
system developed by New England Research Institutes, Inc
(Watertown,Mass). All analyses were performedby using SAS
(SAS Institute Inc, Cary, NC) and SPSS (SPSS Inc, Chicago,
Ill) statistical software. Baseline characteristics of the CEA and
CASpatient groupswere comparedby using the Student t test
for continuous variables and 2 (cell size 5) or Fisher exact
(cell size 5) tests for categorical data. Multivariable regres-
sion analysis using the Cox proportional hazard model was
performed to identify baseline predictive factors for the com-
posite end point of 30-day death, stroke, or AMI and 1-year
death or stroke. Kaplan-Meier estimates of freedom from
events for the primary and secondary end points were deter-
mined; the log-rank test was used to compare primary and
secondary event rates. Differences were considered significant
if P .05. Quality-of-life changes based on theMILQ scores
were compared by using a t test of the net change (baseline to
1 year) compared with 0.
RESULTS
Patient characteristics. A total of 397 patients (254
CEA and 143 CAS) were enrolled in the study. Of the 254
CEApatients, 33%were symptomatic (vs 67% asymptomatic),
and 87%were high risk (vs 13% low risk). Similarly, of the 143
CAS patients, 31%were symptomatic (vs 69% asymptomatic),
and 84% were high risk (vs 16% low risk). Overall baseline
Table I. Baseline demographics and clinical characteristics
Variable CEA (n  25
Demographics
Age, y (mean  SD) 71.4  8.8
Male sex 161 (63%)
Caucasian race 236 (93%)
Height, cm (mean  SD) 169.6  9.8
Weight, kg (mean  SD) 78.5  16.
Risk factors
Symptomatic 83 (33%)
Stenosis diameter
50%-75% 29 (11%)
75% 225 (89%)
Medical history
TIA 69 (27%)
CVA 41 (16%)
TIA or CVA 94 (37%)
CEA before study 29 (11%)
Carotid stent before study 0 (0%)
Prior peripheral angioplasty 1 (0.4%)
Contralateral stenosis 50% 100 (40%)
CAD or previous AMI 154 (61%)
Congestive heart failure 42 (17%)
Hypertension 206 (81%)
Hypercholesterolemia 177 (70%)
Diabetes mellitus 61 (24%)
Peripheral vascular disease 103 (41%)
CEA,Carotid endarterectomy;CAS, carotid stenting systems (with cerebral
coronary artery disease; AMI, acute myocardial infarction.
*n  253 patients.demographics did not differ between the two treatment arms,as seen in Table I.10 For purposes of this article, baseline
characteristics were also stratified by symptoms (Table II) and
surgical risk (Table III), as described by Ouriel et al. 11 The
stratified comparisons between treatment groups were also
not statistically significant, thus further emphasizing the
equivalence of the two treatment arms.
Baseline ultrasound characteristics of target lesions re-
vealed that patients in the CEA arm had statistically signifi-
cantly more stenosis than those in the CAS arm, as demon-
strated by peak systolic velocity (PSV; 302 cm/s CEA vs 202
cm/sCAS;P .01), end-diastolic velocity (100 cm/sCEAvs
61 cm/s CAS; P  .01) and internal carotid artery (ICA)/
CCA PSV ratio (4.4 CEA vs 3.1 CAS; P  .01; Table IV.) The
average baseline stenosis was 80% to 89% in the CEA arm vs
70% to 79% in theCAS arm as determined by ultrasonography
with PSV, end-diastolic velocity, and the ICA/CCA PSV
ratio.14-17 The average percentage stenosis in the CAS arm as
determined by carotid angiography was 82%. Angiography
was not required in the CEA arm.
In the CAS arm, the distribution of stent placement was
40 (28%) of 143 in the ICA, 12 (8%) of 143 in the CCA, and
91 (64%) of 143 in both the ICA andCCA. The average stent
lengthwas 3.66 0.98mm (range, 1.9-6.5mm).Of the 143
CAS procedures, 52%were performed by surgeons, 44%were
performed by interventional cardiologists, and 4% were per-
formed by interventional radiologists.
Primary end points. The Kaplan-Meier curves for the
reatment arm
Treatment arm
P valueCAS (n  143)
71.2  9.6 .85
86 (60%) .52
133 (93%) .97
170.6  10.3 .07
81.9  20.4 .07
44 (31%) .70
.06
8 (6%)
135 (94%)
32 (22%) .29
28 (20%) .39
53 (37%) .99
43 (30%) .01
8 (6%) .01
3 (2%) .14
49 (34%) .30
95 (66%) .25
19 (13%) .39
116 (81%) 1.00
91 (64%) .22
42 (29%) .24
65 (45%) .34
tion); TIA, transient ischemic attack;CVA, cerebrovascular accident;CAD,by t
4)
2
*
protecprimary endpoint of all-cause mortality or stroke at 1-year
action
action
JOURNAL OF VASCULAR SURGERY
August 2005216 CaRESS Steering Committeedemonstrate no statistically significant differences between
curves (Fig 1). Although the CAS rates were consistently
lower than the CEA rates, the most notable difference was in
stroke rates (30 days: 3.6% CEA vs 2.1% CAS, not significant;
1 year: 9.8% CEA vs 5.5% CAS, not significant), which dom-
inated all the combined rates. The death rates remained com-
Table II. Baseline demographics by treatment arm, stratifi
Variable
CEA
Symptomatic
(n  84)
Asympto
(n  1
Age, y (mean  SD) 70.4  9.2 71.9 
% Male 61% 65%
% Caucasian 92% 94%
Height, cm (mean  SD) 168.0  8.6 170.4 
Weight, kg (mean  SD) 77.7  18.4 79.0 
Hypertension 77% 83%
Diabetes mellitus 25% 24%
Hypercholesterolemia 77% 73%
Congestive heart failure 12% 19%
CAD or previous MI 63% 64%
CEA, Carotid endarterectomy; CAS, carotid stenting systems (with cerebra
*The P value for categorical variables is a Cochran-Mantel-Haenszel 2 P val
from an analysis of variance with symptomatology, procedure, and the inter
Table III. Baseline demographics by treatment arm, strat
Variable
CEA
High risk
(n  220)
Low
(n 
Age, y (mean  SD) 71.6  9.1 70.3 
% Male 64% 59
% Caucasian 94% 88
Height, cm (mean  SD) 169.6  9.3 169.6 
Weight, kg (mean  SD) 78.8  16.1 77.2 
Hypertension 81% 82
Diabetes mellitus 22% 41
Hypercholesterolemia 74% 79
Congestive heart failure 17% 12
CAD or previous MI 63% 67
CEA, Carotid endarterectomy; CAS, carotid stenting systems (with cerebra
*The P value for categorical variables is a Cochran-Mantel-Haenszel 2 P val
from an analysis of variance with symptomatology, procedure, and the inter
Table IV. Baseline ultrasound lesion characteristics
between treatment arms
Variable CEA CAS P value
PSV (mean  SD) 302  122 cm/s 202  147 cm/s .01
End-diastolic
velocity
(mean  SD)
100  50 cm/s 61  53 cm/s .01
ICA/CCA PSV
ratio
(mean  SD)
4.4  2.3 3.1  2.8 .01
CEA,Carotid endarterectomy;CAS, carotid stenting systems (with cerebral
protection); PSV, peak systolic velocity; ICA, internal carotid artery; CCA,
common carotid artery.parable across both treatment arms (30 days: 0.4% CEA vs0.0%CAS, not significant; 1 year: 6.6%CEAvs 6.3%CAS, not
significant). The lack of statistical significance is probably due
to the lack of numbers in this preliminary database. Kaplan-
Meier estimates for the end points of all-cause mortality,
stroke, or AMI at 30 days (Table V) showed little change
compared with the primary end points at 1 year (Table VI).
Seven cases ofAMIwere observed: five (2.4%) in theCEAarm
and two (1.7%) in theCASgroup. Twoof the fiveAMIs in the
CEA group occurred within 30 days of the index procedure
(Fig 1).
When adjusted for baseline predictions by using the Cox
proportional hazard regression, the treatment arm differences
at 1 year (Table VII) remained. Hazard ratios less than 1
(treatment, CAS vs CEA) indicated that, controlling for all
other covariates, therewas a lower risk of the composite 1-year
primary end point in the CAS arm.Hazard ratios greater than
1 (for example, age) indicated that, controlling for all other
covariates, there was a greater risk of the composite 1-year
primary end point as age increased. Multivariate analysis did
not show significant baseline predictors of outcome other
y symptomatology
CAS
P value*
Symptomatic
(n  44)
Asymptomatic
(n  99)
68.9  9.2 72.2  9.7 .14
61% 60% .52
91% 94% .99
171.5  9.1 170.3  10.5 .21
84.3  19.5 80.9  20.9 .20
77% 83% .98
25% 31% .26
68% 69% .27
7% 17% .42
57% 74% .31
ection); CAD, coronary artery disease; AMI, myocardial infarction.
stratified variables. The P value for continuous variables is the overall P value
as factors.
by surgical risk
CAS
P value*
High risk
(n  120)
Low risk
(n  23)
71.8  9.8 68.3  8.3 .34
62% 52% .55
92% 100% .97
170.8  10.3 169.9  8.9 .78
82.4  20.9 79.6  18.1 .27
80% 87% .98
30% 26% .28
71% 60% .27
13% 17% .44
71% 57% .29
ection); CAD, coronary artery disease; AMI, myocardial infarction.
stratified variables. The P value for continuous variables is the overall P value
as factors.ed b
matic
70)
8.6
9.4
15.0
l prot
ue forified
risk
34)
6.7
%
%
8.9
16.8
%
%
%
%
%
l prot
ue forthan age (odds ratio, 1.056; P  .0069) and prior carotid
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in Table VII for the 1-year composite end point. Other
factors, such as sex, race, surgical risk, symptomatology, prior
transient ischemic attack or stroke, or percentage stenosis,
were not statistically significant predictors of the primary end
Fig 1. Kaplan-Meier curves at 1 year for combined death/stroke.
CAS, Carotid stenting; CEA, carotid endarterectomy.
Table V. Kaplan-Meier estimates of event rates at 30 days
Variable
All-cause mortality Stroke
CEA CAS CEA CAS
No. at risk 254 143 254 143
No. events 1 0 9 3
No. censored* 26 6 24 5
K-M estimate 0.9957 1.0000 0.9639 0.9786
SE 0.00425 0.0000 0.0118 0.0122
Event rate† 0.4% 0.0% 3.6% 2.1%
P value .445 .408
AMI, Acute myocardial infarction; CEA, carotid endarterectomy; CAS, car
*The number censored includes patients who either terminated before the 3
the patient completed the visit or remained enrolled in the study.
†Calculated as (1  K-M estimate), this represents a person-year rate.
Table VI. Kaplan-Meier estimates of event rates at 1 year
Variable
All-cause mortality Stroke
CEA CAS CEA CAS
No. at risk 254 143 254 143
No. events 14 8 22 7
No. censored* 108 49 106 53
K-M estimate 0.9337 0.9373 0.9018 0.9450
SE 0.0172 0.0215 0.0201 0.0204
Event rate† 6.6% 6.3% 9.8% 5.5%
P value .893 .133
AMI, Acute myocardial infarction; CEA, carotid endarterectomy; CAS, car
*The number censored includes patients who either terminated before the 1
the patient completed the visit or remained enrolled in the study.
†Calculated as (1  K-M estimate), this represents a person-year rate.points.Secondary end points. The 1-year event rates observed
for secondary end points are summarized in Table VIII. The
CAS arm had consistently higher rates of residual stenosis
rimary end points
AMI
Combined
death/stroke
Combined
death/stroke/AMI
A CAS CEA CAS CEA CAS
4 143 254 143 254 143
2 0 9 3 11 3
7 6 24 5 24 5
21 1.0000 0.9639 0.9786 0.9560 0.9786
555 0.0000 0.0118 0.0122 0.0130 0.0122
8% 0.0% 3.6% 2.1% 4.4% 2.1%
.291 .408 .241
enting systems (with cerebral protection); K-M, Kaplan-Meier.
follow-up or for whom specific 30-day data were not obtained even though
rimary end points
AMI
Combined
death/stroke
Combined
death/stroke/AMI
A CAS CEA CAS CEA CAS
4 143 254 143 254 143
5 2 30 13 32 14
9 59 98 47 98 47
63 0.9826 0.8643 0.8998 0.8568 0.8910
07 0.0122 0.0233 0.0265 0.0237 0.0277
% 1.7% 13.6% 10.0% 14.3% 10.9%
.619 .302 .288
enting systems (with cerebral protection); K-M, Kaplan-Meier.
follow-up or for whom specific 1-year data were not obtained even though
Table VII. Cox proportional hazard regression of
baseline predictive factors for the composite end point of
death, stroke, or myocardial infarction at 0 to 30 days
plus death or stroke at 31 days to 1 year (analysis of
maximum likelihood estimates)
Variable
Hazard
ratio
95% Hazard ratio
confidence
limits P value
CAS vs CEA 0.552 0.276-1.101 .0917
Age 1.056 1.015-1.098 .0069
Female 1.755 0.950-3.244 .0726
Non-Caucasian 1.050 0.318-3.465 .9365
Symptomatology 1.264 0.568-2.815 .5660
Risk 1.915 0.581-6.312 .2857
% Stenosis 1.165 0.375-3.624 .7916
Prior TIA or CVA 1.334 0.645-2.759 .4365
Prior carotid procedures 2.786 1.433-5.419 .0025
CEA,Carotid endarterectomy;CAS, carotid stenting systems (with cerebral
protection); TIA, transient ischemic attack; CVA, cerebrovascular accident.for p
CE
25
2
0.99
0.00
0.
otid st
0-dayfor p
CE
25
11
0.97
0.01
2.4
otid st
-year(0.9% CAS vs 0% CEA), restenosis (6.3% CAS vs 3.6% CEA),
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revascularization (1.8% CAS vs 1.0% CEA), but, as antici-
pated, none was statistically significant, given the small num-
bers of prior procedures reported.
The changes in quality of life between baseline and 1 year
were also evaluated by using the MILQ scores. Figure 2 shows
the baseline distributions of MILQ scores (possible range,
12-84) for each treatment arm. The wide range of scores
reflects the broad range of patients recruited into the study.
However, there was no statistically significant difference in
baseline scores between treatment groups (66 points in the
CEA group vs 64 points in the CAS group). There were 191
patients (119 CEA and 72 CAS) with MILQ scores at both
baseline and 1 year. Scores were imputed for 16 patients who
died before the 1-year visit. In addition, whereas the CAS arm
experienced a greater decline in quality of life (4.22 points
CAS vs1.56 points CEA; P .319), it was not statistically
significant.
DISCUSSION
The CaRESS study was initiated to address the utility of
CASwith embolic protection for treating carotid artery occlu-
sive disease in current clinical practice. An essential premise of
CaRESS is that the evaluation of the safety and efficacy ofCAS
compared with CEA should not be limited to a high-risk
population.
The overall baseline characteristics were remarkably ho-
mogenous between treatment groups, with the exception that
the CAS arm had more patients who had previous carotid
intervention, which was expected.18 It is noteworthy that,
when adjusted for risk or symptomatology, there was still no
statistically significant difference in baseline characteristics.
This suggests reasonable equivalence in the non–randomly
assigned treatment arms.
When compared with the 30-day event rates summarized
in Table V, the trend toward longer event-free survival in the
CAS arm at 1 year (Table VI) for the primary end points
reported here may be artifactual in this phase I study, but it is
interesting nonetheless. This trend is particularly noteworthy
given the significant effect (hazard ratio) in the opposite
Fig 2. Baseline distribution (percentage) of Multidimensional
Index of Life Quality (MILQ) scores by treatment group. CAS,
Carotid stenting; CEA, carotid endarterectomy.direction for prior carotid procedures (Table VII). Ratherthan indicating that the CAS group is sicker than the CEA
group at baseline, the higher prior intervention rate in the
CAS group may, indeed, be an indicator of their relative
health. Theymay bemore likely to be considered for multiple
procedures if their risk is perceived to be adequately low.
The composite 1-year rates observed in CaRESS
were comparable to the rates observed in the ARCHeR,
SAPPHiRE, MAVErIC, and CABernET studies.2-5 The
somewhat higher stroke rates than those reported for
NASCET7 and ACAS8 may reflect different diagnostic criteria
and the lack of rigorous eligibility criteria typical of most
randomized trials. Certainly, the plan to include in CaRESS a
broad profile of patients typically offered CAS or CEA seems
to have been successful in the sense that outcome rates were
not lower than those reported by comparable studies, despite
the inclusion of a majority of asymptomatic patients.
Despite the potential for bias in themeanMILQ scores, it
is noteworthy that the treatment group comparison at 1 year
was not statistically significant (P  .319) and that baseline
scores were comparable. The MILQ scores thus reaffirm the
broad patient representation.
The CaRESS study is the only study conducted thus far
that attempts to imitate the true clinical environment. In this
population of both low- and high-risk patients, the 30-day
composite morbidity andmortality rates of 4.4% for CEA and
2.1% for CAS compare well with both NASCET and ACAS.
Furthermore, CaRESS compares favorably with the already
published high-risk registries or trials using distal protection in
which the major adverse event rates at 30 days were 3.8% to
8.2% (ARCHeR, Boston Scientific EPI. A carotid stenting
trial for high-risk surgical patients (BEACH), CABernET,
MAVErIC, and SAPPHiRE). The most easily compared
high-risk trial, SAPPHiRE, had 30-day major adverse event
rates of 12.6% for CEA and 5.8% for CAS. The cumulative
1-yearmajor adverse event rates in SAPPHiREwere 20.1% for
CEA and 12.2% for CAS; those in CaRESS were 14.3% vs
10.9%, respectively. Although we await the results of the
CREST trial as a randomized, prospective study on which to
base clinical decisions between CAS and CEA, the CaRESS
trial likely reflects more accurately the true decision-making
process that will occur when CAS is eventually approved by
theCenters forMedicare andMedicaid Services. TheCaRESS
phase II trial will be able to provide adequate sample size and
power to demonstrate equivalence between the two treatment
Table VIII. Person-year rates at 1-year follow-up for
additional end points by treatment arm
Variable CEA CAS P value
Restenosis 7/192 (3.6%) 7/111 (6.3%) .296
Residual stenosis 0/192 (0.0%) 1/111 (0.9%) .366
Carotid
revascularization
2/192 (1.0%) 2/112 (1.8%) .627
Repeat angiography 4/192 (2.1%) 4/112 (3.6%) .472
CEA,Carotid endarterectomy;CAS, carotid stenting systems (with cerebral
protection).arms.
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The CaRESS phase I study suggests that the risk of death
or stroke 1 year after CAS by using distal protection is equiv-
alent to that after CEA in a broad-category population with
carotid stenosis. TheCaRESSphase 1 studywas able to closely
resemble clinical practice by enrolling patients on the basis of
the degree of carotid stenosis and symptomatology rather
than surgical risk. This uniquely designed trial allows multiple
CAS manufacturers to participate and use the resulting data
for a broad-risk premarket application submission. As such,
CaRESS phase II will be able to establish the precedent of
commercialization based on a definablesymptomatology
rather than a variable surgical risk definition. Funding for
CaRESS phase II is pending.
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